ArticleFrontiers in public health2025
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov's model-based evaluation.
Juan Hong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.